Clear Thinking. Clear Value.
Enhancing cardiovascular outcomes through the design and conduct of clinical trials that investigate
innovative therapies.
Over 60 manuscripts since 2015 from PARTNER I and PARTNER II, including landmark papers in The New England Journal of Medicine, JAMA, and The Lancet.
Learn More
The JETSTREAM Calcium study showed increased lumen dimensions by IVUS in femoral-popliteal lesions by removing superficial calcium with the Jetstream Atherectomy System without major complications.
Learn More
The CRF Publications Office has published over 300 papers since 2007 from ACUITY, HORIZONS-AMI, INFUSE-AMI, PROSPECT, and other studies.
Learn More
HORIZONS-AMI investigators found that sustained ventricular tachycardia/fibrillation after primary PCI was not significantly associated with 3-year mortality or major adverse clinical events.
Learn More
NIRS imaging used to detect lipid core containing plaque in the CANARY, YELLOW, and COLOR studies was analyzed at the CRF IVI Core Lab.
Learn More
PARTNER investigators found that the relationship between moderate/severe pulmonary hypertension and increased mortality after TAVR is altered by sex, and clinical factors appear to be more influential in stratifying risk than hemodynamic indices.
Learn More
In the HORIZONS-AMI trial, the development of new-onset congestive heart failure within 2 years after contemporary PCI, although infrequent, was associated with significantly increased rates of mortality and major adverse ischemic events.
Learn More
Why Us?
- The CTC offers a unique combination of services that focus on improving cardiovascular outcomes
through the design and execution of clinical trials that investigate innovative therapies
- Scientific leadership with unparalleled expertise
- Experience in planning and overseeing some of the most influential clinical trials in
interventional cardiology
- Strategic partnerships that guide promising ideas to the marketplace at all stages of a company
life cycle, from the smallest of start-ups to the largest NASDAQ-listed players
- Scientifically robust state-of-the-art core labs
- Regulatory experience, including numerous presentations to the FDA
- A committed operations team, in addition to comprehensive and sophisticated evaluation and
analysis services
Key Statistics:
- CTC has been involved in over 700 clinical trials, amassing data on more than 200,000 patients
- More than 100 active projects
- Strong relationships with over 130 sponsors and institutions
- Conducts image analyses of more than 10,000 subjects per year
- Adjudicates over 3,000 clinical events and endpoints per year